Labiotech.eu - Europe's leading Biotech News Website

Latest Posts

News and Trends 8 Feb 2016

French Biotech Launches Phase III Global Trial for Lung Cancer Drug

OSE Pharma (France) has initiated the US phase III trial, Atalante 1. This global, pivotal trial will evaluate Tedopi, the company’s lead product, for advanced non-small cell lung cancer (NSCLC). The phase III study was initiated in Europe in early 2016, so the screening of eligible patients diagnosed with non-small cell lung cancer is now actively ongoing in […]

February 8, 2016 - 2 minutesmins - By Dani Bancroft

News and Trends 8 Feb 2016

Here are 8 of Forbes’ Under 30 Year Olds Transforming European Biotech

Here are 8 of the top European innovators under 30 which are part of the Biotech Ecosystem… After reading Forbes ’30 Under 30′ ranking in the Science and Healthcare field in Europe, we decided to list a few of these impressive individuals – one as young as 18 years old! The panel of judges was made up […]

February 8, 2016 - 4 minutesmins - By Dani Bancroft

News and Trends 7 Feb 2016

What happened this week? CRISPR, Microbiome, Algae in Biotech

Monday: Huge Milestone: UK Approves CRISPR Editing on Human Embryos Tuesday: Ultimate Review: The Unlimited Biotech Potential of Algae Wednesday: Meet the CEO of Europe’s Leading Microbiome Biotech Thursday: Zika Virus: Who in Biotech is Working to Stop its Spread? Friday: German RNA Specialist Could Break French Biotech into the Cancer Ecosystem Bonus: How we […]

February 7, 2016 - 1 minutemin - By Philip Hemme

News and Trends 5 Feb 2016

Biotech of the week: Effimune, the French Success-story in autoimmune disease

This week, we leave central Spain and head North-East, across the Pyrenees and head to the largest city in ‘Traditional Brittany’, France, and also the this week’s location, Nantes. This picturesque city was voted the most Green in EU (2013), is famous for the production of Muscadet wine and is home to our biotech of […]

February 5, 2016 - 2 minutesmins - By Philip Hemme

News and Trends 5 Feb 2016

German RNA Specialist Could Break French Biotech into the Cancer Ecosystem

Riboxx Life Sciences (Germany) has licensed out its drug development platform APOXXIM to a small biotech, Tollys SAS in Lyon (France) to investigate a specific type of cancer therapy. Riboxx develops customized and tailor-made molecular tools for gene silencing in vitro and in vivo through RNA interference via small interfering RNA (siRNA) and microRNA (miRNA). The company has two […]

February 5, 2016 - 2 minutesmins - By Dani Bancroft

News and Trends 4 Feb 2016

Zika Virus: Who in Biotech is Working to Stop its Spread?

The Zika virus epidemic could infect up to 4 Million people. As a cousin to Dengue Fever, what are the risks? Who in the Biotech and pharma world are working on a vaccine? And what is exactly this virus which has everyone hot and bothered? Literally meaning ‘overgrown‘ in the Luganda language, the Zika Virus name comes from the […]

February 4, 2016 - 4 minutesmins - By Nicolas Sainte-Foie

ADVERTISEMENT

News and Trends 4 Feb 2016

Finland, France and Harvard Bioprint Brains to Understand the 3D Structure

Researchers at Harvard University in collaboration with French and Finnish academic institutions have managed to 3D-bioprint a brain with the distinctive folds; An essential adaptation for our cognitive development. Harvard University worked with the CNRS at Aix Marseille Université (France), Institut Mines-Telecom INSERM (France) and the University of Jyväskylä (Finland). The team then published in Nature Physics what they discovered […]

February 4, 2016 - 3 minutesmins - By Dani Bancroft

Philip Joachim Jan16 Labiotech

Inside Labiotech 4 Feb 2016

How we Raised our First Seed Round to Build the Next TechCrunch for Biotech

You may have read it on Tech.eu (the biggest EU Startup blog), Gründerszene (the biggest German startup magazine) or in Maddyness (the biggest French Startup magazine) yesterday: Yes, we raised our first seed fundraising to become ‘the next TechCrunch’ for Biotech! The 6-figure seed round was raised with our lead investor WestTech Ventures as well as 4 European business […]

February 4, 2016 - 6 minutesmins - By Philip Hemme

News and Trends 3 Feb 2016

When the Llama met the Lion: Antibodies Unlock Milestone Payment for Skin Disease

ArGEN-X in Ghent (Belgium) combines the diversity of the llama immune system with a clinical antibody pipeline which Leo Pharma (Denmark), is developing to treat inflammatory skin conditions. These llama mAb platforms allow arGEN-X to unlock novel and complex targets and develop antibody-based drugs designed for longer duration of effect and greater efficacy. This is a similar approach to which Ablynx […]

February 3, 2016 - 2 minutesmins - By Dani Bancroft

News and Trends 3 Feb 2016

France’s 3rd Largest Pharma Company Finally Opens up to Biotech Innovation

Open Innovation is now everywhere, even Pharma. So, just today in France, the opening of the Pierre Fabre Fund for Innovation for biotech startups has been announced. Most Big Pharma have their own program. Boehringer-Ingelheim for example is partnering with BioMedX to run a new program with researchers from Heidelberg. Now the 3rd largest Pharma company in France, […]

February 3, 2016 - 2 minutesmins - By Philip Hemme

News and Trends 3 Feb 2016

Meet the CEO of Europe’s Leading Microbiome Biotech

We met Pierre Belichard, the CEO of Enterome, last week to discuss the increasingly famous trend in the Human Microbiome and how this is impacting therapeutics in Crohn’s disease, the understanding of Medical Microbiomics and investment in this field of Biotech. Enterome, established in 2012, is a French biotech that is hot at the moment, […]

February 3, 2016 - 5 minutesmins - By Philip Hemme

News and Trends 2 Feb 2016

From Belgium: 3D-Bioprinted ‘Waffle’ to Fix Broken Bones

Bone Therapeutics (Belgium) is a cell therapy biotech working on bone fracture repair which has now extended its collaboration with Kasios (France), to develop next-generation bone disease therapy with 3D-Bioprinting technology. The current standard-of-care in the Bones field involves major surgeries and (consequently) long recovery time. Bone Therapeutics is, therefore, developing a range of regenerative products containing osteoblasts (bone-forming cells), which […]

February 2, 2016 - 3 minutesmins - By Dani Bancroft

ADVERTISEMENT